Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.

Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45.

View in: PubMed